The clinical pharmacist attributed the thrombocytopenia to voriconazole exacerbating the hematological toxicity of selpercatinib and thus stopped selpercatinib and voriconazole treatment sequentially; the patient was given recombinant human thrombopoietin to raise platelets. Here, THPO is linked to Thrombocytopenia.